Anti-TPO IgE Autoantibody in Chronic Urticaria: Is It Clinically Relevant?

Ulambayar, Bastsetseg; Park, Hae‐Sim

doi:10.4168/aair.2019.11.1.1

Cited by 6 publications

(4 citation statements)

References 20 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated prevalence rates of IgE and IgG anti-thyroid autoantibodies (AAbs) in CSU patients from different populations and ethnicities have been observed ( Supplementary Table S1 ). 2 Anti-thyroid IgG AAbs cause autoimmune thyroid inflammation, disrupts normal architecture of the thyroid gland, leads to release of sequestered autoantigens, such as thyroid peroxidase (TPO) and/or thyroglobulin (TG), and induce a low-grade autoimmune response. The resulting thyroid protein immune complexes activate the classic complement pathway to generate C3a and C5a, which cause degranulation of mast cells.…”

Section: Introductionmentioning

confidence: 99%

IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review

Zhang

Qiu

et al. 2022

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Immunoglobulin (Ig) E and IgG anti-thyroid autoantibodies (AAbs) play important roles in the immunopathogenesis of chronic spontaneous urticaria (CSU). To date, association of IgE and IgG AAbs with Chinese CSU patients has not been fully investigated. We aimed to explore prevalence rates of IgE and IgG AAbs in Chinese CSU patients and their association with clinical and laboratory parameters. Serum IgE and IgG AAbs against thyroid peroxidase (TPO) and thyroglobulin (TG), total IgE (tIgE) and specific IgEs were measured using enzyme-linked immunosorbent assay, chemiluminescence microparticle immunoassay and immunoblotting. Meta-analyses and literature review were conducted. The meta-analyses indicated that CSU cases were 4.98, 6.90 and 6.68 times more likely to have positive anti-TPO IgE, anti-TPO IgG and anti-TG IgG (all P < 0.001) compared with controls, respectively, and revealed a positive correlation between the prevalence rates of anti-TPO IgE and anti-TPO IgG ( r = 0.53, P = 0.025). A total of 1,100 Chinese Han adult CSU patients and 1,100 ethnicity-, age- and sex-matched healthy controls were recruited from 15 centers. Prevalence rates of anti-TPO IgE, anti-TPO IgG, anti-TG IgE or anti-TG IgG in the patients were all significantly higher than those in the controls. Significant correlations were observed between prevalence rates of anti-TPO IgE and anti-TPO IgG ( r = 0.297, P < 0.001) as well as between those of anti-TG IgE and anti-TG IgG in the patients ( r = 0.137, P < 0.001). Patients with anti-TPO IgE or anti-TPO IgG had significantly lower tIgE levels ( P < 0.001). Positive anti-TPO IgE, positive anti-TPO IgG and tIgE < 40 IU/mL were independent predictors of antihistamine-refractory cases. In conclusion, the prevalence rates of IgE and IgG AAbs in Chinese CSU patients are significantly elevated and reciprocally correlated. This study verifies the results of previous case-control studies of CSU patients from other populations and ethnicities.

show abstract

Section: Introductionmentioning

confidence: 99%

IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review

Zhang

Qiu

et al. 2022

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…We screened patient serum for anti-IL-24 IgE, anti-TPO IgE, and anti-Fc epsilon receptor (FcεRI) IgG levels, which are reported to be upregulated in patients with CSU [ [44] , [45] , [46] ]. The anti-IL-24 IgE (1.5 ± 0.4-fold increase; P = 6.1 × 10 −6 ) and anti-FcεRI levels (relative 6.7 ± 1.2% increase, P = 0.022) in the SARS-COV-2 vaccines-induced CU group were significantly higher than those in the SARS-COV-2 vaccines-tolerant controls and non-CU patients ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…A further analysis of autoreactive IgE-autoantibodies (anti-IL-24) and IgG-autoantibodies (e.g., anti-TPO, anti-FcεRI, anti-TYMS and anti-THRA) were significantly increased in these CU patients compared with those in tolerant subjects. Specific IgE and IgG autoantibodies are known to be involved in the pathogenesis of CSU [ [44] , [45] , [46] , 54 ]. It has been reported that lower total IgE level [ 55 ], and higher IgE-anti-IL-24 [ 44 ]/anti-IgG-anti-TPO autoantibodies [ [55] , [56] , [57] ] levels are found in autoimmune CSU patients.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by SARS-CoV-2 vaccines

Wang

Chen

et al. 2023

Journal of Autoimmunity

View full text Add to dashboard Cite

“…The activation and release of in ammatory mediators by mast cells are the primary pathophysiologies of CSU. Immunoglobulin E (IgE) is known to activate mast cells by binding to the high-a nity receptor of IgE (FcεR ) 2,5 . The drug treatment of CSU is mainly based on its pathological mechanism.…”

Section: Introductionmentioning

confidence: 99%

Temporal, drug dose, and sample size trends in the efficacy of omalizumab for chronic spontaneous urticaria: a cumulative meta-analysis

Qin

Xiao

et al. 2023

Preprint

View full text Add to dashboard Cite

Omalizumab is a humanized anti-IgE, which is indicated for managing chronic spontaneous urticaria (CSU). The dynamic change trend of the efficacy of omalizumab for CSU is unclear. We searched Cochrane, OVID, Embase, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) of omalizumab versus placebo in CSU patients from inception to January 2023. The primary outcome was the percentage of complete responders (defined as the weekly urticaria activity score as 0, UAS7 = 0). Secondary outcomes were the percentage of participants with UAS7 ≤ 6, the percentage of weekly itch severity score minimally necessary difference responders (defined as a reduction from baseline in ISS7 of ≥ 5 points, ISS7 MID), and adverse events (AEs). 12 randomized, placebo-controlled studies with 2166 patients with CSU were included. Compared with the placebo, the omalizumab group significantly improved UAS7 = 0, UAS7 ≤ 6, and the percentage of ISS7 MID responders. Over the order of publication time, drug dose, and sample size increased, the efficacy had become more stable and accurate. It was recommended to increase studies with high quality and large samples and to reduce blind repetitive RCTs to avoid wasting scientific and medical resources.

show abstract

Anti-TPO IgE Autoantibody in Chronic Urticaria: Is It Clinically Relevant?

Cited by 6 publications

References 20 publications

IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review

IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review

Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by SARS-CoV-2 vaccines

Temporal, drug dose, and sample size trends in the efficacy of omalizumab for chronic spontaneous urticaria: a cumulative meta-analysis

Contact Info

Product

Resources

About